Sep 11, 2019
Similar Response Rate but Higher Degrees of Clinical Improvement Were More Likely to Achieve With Cariprazine Compared to Risperidone - A Study by Gedeon Richter Plc
May 28, 2019
Allergan and Gedeon Richter Receive U.S. FDA Approval For Expanded Use of VRAYLAR® (cariprazine) in the Treatment of Bipolar Depression
May 15, 2019
Allergan to Present VRAYLAR® (cariprazine) Data at the American Psychiatric Association (APA) 2019 Annual Meeting Highlighting Continued Commitment to Mental Health
Apr 16, 2019
Cariprazine Shows Better Cognitive Improving Features and Uniquely Favorable Weight Gain Effect Compared to Other Antipsychotics
Sep 26, 2018
Allergan Announces FDA Acceptance of Supplemental New Drug Application For VRAYLAR® (cariprazine)
May 02, 2018
Allergan to Present Data from a Robust Mental Health Clinical Program at the American Psychiatric Association (APA) 2018 Annual Meeting
Apr 03, 2018
Allergan and Richter Announce Positive Topline Results from Third of Three Pivotal Trials of Cariprazine in Bipolar I Depression
Dec 18, 2017
Allergan and Richter Announce Positive Topline Results from Phase 3 Study of Cariprazine for the Treatment of Bipolar I Depression
Nov 13, 2017
Allergan Receives FDA Approval For Use of VRAYLAR(TM) (cariprazine) in the Maintenance Treatment of Schizophrenia
Sep 22, 2017
Allergan Receives Refusal to File Letter from FDA for Vraylar® (cariprazine) Supplemental New Drug Application (sNDA) for the Treatment of Negative Symptoms in Schizophrenia